ClinicalTrials.gg
RecruitingNCT06295861Updated Nov 16, 2026

Prospective Cohort Study of Panvascular Disease in China(PAN-China)

An observational study in ASCVD, sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine. Recruiting at 3 sites in China. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine · Observational

How we know

From the registry’s dates

  • Started Feb 2024; still recruiting 2 years 9 months later.
Updated Nov 16, 2026Now RecruitingSite recruiting status changed+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
50,000
Ages
18 Years and older
Sex
All
01

Study summary

To construct a comprehensive big data platform for Chinese people with panvascular disease, and establish a Chinese panvascular disease oriented to guide treatment decisions Cohort and imaging, biological database; According to the clinical features, morphological structure, pathological characteristics of panvascularization, vascular age As the core of the evaluation, a standard evaluation system and a risk prediction model of intervention technology suitable for the diagnosis and treatment of patients with panvascular disease in China were established. Into the Further optimize the treatment strategies, protocols and clinical pathways for panvascular disease to improve patient prognosis and promote its application.

Read the detailed description

3.2 Selection of Research Subjects (1) Inclusion Criteria:

  1. Age ≥18 years old
  2. Meet the inclusion criteria of any one of the following groups: Group A. Patients with pan-vascular diseases: This refers to those involving two or more of the following vascular diseases. 2.1 Coronary Arteries:

2.1.1 Coronary atherosclerotic heart disease: It includes acute coronary syndrome, stable angina pectoris, moderate to severe coronary artery stenosis, history of myocardial infarction, and history of coronary revascularization such as stent implantation or bypass grafting.

2.2. Cerebrovascular diseases: □2.2.1 Intracranial atherosclerotic diseases: including ischemic stroke, transient ischemic attack or moderate intracranial artery disease The above is narrow. □2.2.2 Carotid atherosclerotic diseases: including carotid artery disease and vertebral artery disease.

2.3. Aorta: □2.3.1 Atherosclerotic aortic diseases: including severe aortic plaques, aortic ulcers, aortic stenosis or atresia,

Aortic dissection, aortic aneurysm, etc. 2.4. Peripheral Arteries:

Compare the prediction models.

□2.4.1 Atherosclerotic diseases of the upper extremities: including diseases of the subclavian artery, axillary artery, brachial artery and other parts.

The 3rd Edition May 8, 2026 □2.4.3 Mesenteric atherosclerotic disease □2.4.2 Atherosclerotic disease of the renal artery □2.4.4 Atherosclerotic disease of the lower extremity arteries Group B. Patients with a single atherosclerotic vascular disease of the above-mentioned arteries. Group C. People at risk of pan-vascular disease. Have at least one of the following: Abdominal obesity: Waist circumference ≥90cm for men and ≥85cm for women; Fasting blood glucose ≥6.1mmol/L and/or 2-hour postprandial blood glucose ≥7.8mmol/L, and/or diabetes has been diagnosed and treated Healer; Those with blood pressure ≥130/85 MMHG and/or who have been diagnosed with hypertension and are receiving treatment; Those with fasting high-density lipoprotein cholesterol \<1.04mmol/L, and/or those who have been diagnosed with hyperlipidemia and are receiving treatment. 3. The subject or the legal representative of the subject is informed of the nature of this study and agrees to participate in all the terms of this study, and signs each

Informed consent form approved by the ethics committee of the clinical center. (2) Exclusion criteria:

1. Concurrent malignant tumors under treatment (such as during radiotherapy, chemotherapy, surgery, etc.) 2. Concurrent diseases requiring urgent treatment (this item is not excluded after the condition has been stabilized after treatment): such as acute infection, hyperemia Pressure crisis, diabetic ketoacidosis, aortic dissection, etc 3. Currently suffering from severe heart failure (NYHA grade 4) 4. Currently suffering from liver failure (ALT or AST≥ 5 times the upper limit of normal) or current renal failure (any cause of renal function decline (defined as eGFR\<15mL/(min·1.73m2) or currently undergoing dialysis treatment) 5. Women who are pregnant or breastfeeding, or those planning to become pregnant during the research period. 6. Those with severe mental illnesses (except for mild to moderate anxiety and depression) 7. Organ transplantation 8. Expected survival period \<3 years 9. Blood-borne infectious diseases: including HIV infection, AIDS, active hepatitis B, hepatitis C, etc. 10. Any situation in which the researchers consider it unsuitable to participate in the study.

02

Conditions studied

  • ASCVD
03

In context

Lead sponsor

Second Affiliated Hospital, Zhejiang University, School of Medicine is the lead sponsor of 108 studies on the registry; 73 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Nov 16, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

This is a prospective cohort study with 50,000 patients.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years old.
  • Meet the inclusion criteria of any one of the following groups:

Group A: Patients with pan-vascular diseases. This refers to those involving two or more of the following vascular diseases:

Coronary arteries: Coronary atherosclerotic heart disease, including acute coronary syndrome, stable angina pectoris, moderate to severe coronary artery stenosis, history of myocardial infarction, and history of coronary revascularization such as stent implantation or bypass grafting.

Cerebrovascular diseases: Intracranial atherosclerotic diseases, including ischemic stroke, , or moderate intracranial artery disease.

Cerebrovascular diseases: Carotid atherosclerotic diseases, including carotid artery disease and vertebral artery disease.

Aorta: Atherosclerotic aortic diseases, including severe aortic plaques, aortic ulcers, aortic stenosis or atresia, aortic dissection, aortic aneurysm, etc.

Peripheral arteries: Atherosclerotic diseases of the upper extremities, including diseases of the subclavian artery, axillary artery, brachial artery, and other parts.

Peripheral arteries: Mesenteric atherosclerotic disease.

Peripheral arteries: Atherosclerotic disease of the renal artery.

Peripheral arteries: Atherosclerotic disease of the lower extremity arteries.

Group B: Patients with a single atherosclerotic vascular disease of the above-mentioned arteries.

Group C: People at risk of pan-vascular disease. Must have at least one of the following:

Abdominal obesity: Waist circumference ≥ 90 cm for men and ≥ 85 cm for women.

Fasting blood glucose ≥ 6.1 mmol/L and/or 2-hour postprandial blood glucose ≥ 7.8 mmol/L, and/or diabetes has been diagnosed and treated.

Blood pressure ≥ 130/85 mmHg and/or have been diagnosed with hypertension and are receiving treatment.

Fasting high-density lipoprotein cholesterol \< 1.04 mmol/L, and/or have been diagnosed with hyperlipidemia and are receiving treatment.

-The subject or the legal representative of the subject is informed of the nature of this study and agrees to participate in all the terms of this study, and signs the form approved by the ethics committee of the clinical center.

Exclusion criteria

Exclusion Criteria:

  • Concurrent malignant tumors under treatment (such as during radiotherapy, chemotherapy, surgery, etc.).
  • Concurrent diseases requiring urgent treatment (this item is not excluded after the condition has been stabilized after treatment), such as acute infection, hypertensive crisis, diabetic ketoacidosis, aortic dissection, etc.
  • Currently suffering from severe heart failure ( grade 4).
  • Currently suffering from liver failure ( or AST ≥ 5 times the ) or current renal failure (any cause of renal function decline defined as \< 15 mL/(min·1.73m2) or currently undergoing dialysis treatment).
  • Women who are pregnant or breastfeeding, or those planning to become pregnant during the research period.
  • Those with severe mental illnesses (except for mild to moderate anxiety and depression).
  • Organ transplantation.
  • Expected survival period \< 3 years.
  • Blood-borne infectious diseases, including infection, AIDS, active , , etc.
  • Any situation in which the researchers consider it unsuitable to participate in the study.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
50,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients with panvascular disease cohort

    The patient had atherosclerosis in 2 or more vessels

    Other: no different intervention between the two cohort.

  • Patients with single disease cohort

    The patient had atherosclerosis in 1 vessel

  • High risk cohort

    individuals at high risk of ASCVD or suffering from metabolic syndrome

Interventions

  • Otherno different intervention between the two cohort.

    no different intervention between the two cohort.

06

What researchers measure

Primary outcomes

  1. Cardiovascular adverse events

    Time frame: 1, 3, and 5 years follow-up

  2. Cardiovascular mortality

    Time frame: 1, 3, and 5 years follow-up

Secondary outcomes

  1. Rate of receiving vascular revascularization

    Time frame: 1, 3, and 5 years follow-up

  2. Readmission rate for vascular reasons

    Time frame: 1, 3, and 5 years follow-up

07

Study locations

1 of 3 sites recruiting
  • Department of Cardiology, The Second Affiliated Hospital, School of Medicine, Zhejiang University
    Hangzhou, Zhejiang 310000, China
    Active, not recruiting

    Not enrolling at this site.

  • Second Affiliated Hospital, School of Medicine, Zhejiang University
    Hangzhou, Zhejiang 310000, China
    Active, not recruiting

    Not enrolling at this site.

  • The Second Affiliated Hospital of Zhejiang University School of Medicine
    Hangzhou, Zhejiang, China
    Recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2024 (actual). Primary completion is estimated for Nov 2028, 57 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 29, 2024
First posted
Mar 6, 2024
StartActual
Feb 21, 2024
Primary completionEst.
Nov 30, 2028
CompletionEst.
Dec 31, 2028
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Recruiting
changed Nov 16, 2026
Sites
1 site added. 2 sites changed recruiting status (2 now active, not recruiting)
Show 2 sites
  • Department of Cardiology, The Second Affiliated Hospital, School of Medicine, Zhejiang University · Hangzhou, Chinano status→Active, not recruiting
  • Second Affiliated Hospital, School of Medicine, Zhejiang University · Hangzhou, Chinano status→Active, not recruiting
Show site
  • The Second Affiliated Hospital of Zhejiang University School of Medicine · Hangzhou, China
Nov 16, 2026
Eligibility
5 inclusion criteria edited, 13 added, 2 removed; 1 exclusion criterion edited, 9 added, 2 removed
What changed in the criteria
Inclusion criteria
  • Removed1. Age ≥18 years old 2. Patients with panvascular disease: i.e., 2 or more of the following vascular diseases.
  • AddedAge ≥ 18 years old.
  • AddedMeet the inclusion criteria of any one of the following groups:
  • AddedGroup A: Patients with pan-vascular diseases. This refers to those involving two or more of the following vascular diseases:
  • Edited2.1 Coronary arteryarteries: 2.1.1 Coronary atherosclerotic heart disease:, including acute coronary syndrome, stable angina pectoris, moderate or more stenosis of theto severe coronary artery stenosis, history of myocardial infarction, and history of coronary revascularization such as stent implantation or bypass grafting.
  • Edited2.2. CerebrovascularCerebrovascular diseases: 2.2.1 Intracranial atherosclerotic disease:diseases, including ischemic stroke, transient ischemic attack, or moderate or more stenosis of the intracranial artery disease.
  • Edited2.2.2 CervicalCerebrovascular diseases: Carotid atherosclerotic disease:diseases, including carotid artery disease, and vertebral artery disease.
  • Edited2.3. Aorta: 2.3.1 Aortic atherosclerotic disease:Atherosclerotic aortic diseases, including severe aortic plaqueplaques, aortic ulcerulcers, aortic stenosis or atresia, aortic dissection, aortic aneurysm, etc.
  • Edited2.4. Peripheral arteries: 2.4.1 Upper limb atherosclerotic disease:Atherosclerotic diseases of the upper extremities, including diseases of the subclavian artery, axillary artery, brachial artery, and other sitesparts.
  • RemovedEdition 2 January 25, 2024 2.4.2 Renal atherosclerotic disease 2.4.3 Mesenteric atherosclerotic disease 2.4.4 Lower limb atherosclerotic disease 3. Clinical data and biological samples are available 4. The subjects or their legal representatives were informed of the nature of the study and agreed to all terms of participation in the study, and signed the informed consent approved by the ethics committee of each clinical center.
  • AddedPeripheral arteries: Mesenteric atherosclerotic disease.
  • AddedPeripheral arteries: Atherosclerotic disease of the renal artery.
  • AddedPeripheral arteries: Atherosclerotic disease of the lower extremity arteries.
  • AddedGroup B: Patients with a single atherosclerotic vascular disease of the above-mentioned arteries.
  • AddedGroup C: People at risk of pan-vascular disease. Must have at least one of the following:
  • AddedAbdominal obesity: Waist circumference ≥ 90 cm for men and ≥ 85 cm for women.
  • AddedFasting blood glucose ≥ 6.1 mmol/L and/or 2-hour postprandial blood glucose ≥ 7.8 mmol/L, and/or diabetes has been diagnosed and treated.
  • AddedBlood pressure ≥ 130/85 mmHg and/or have been diagnosed with hypertension and are receiving treatment.
  • AddedFasting high-density lipoprotein cholesterol < 1.04 mmol/L, and/or have been diagnosed with hyperlipidemia and are receiving treatment.
  • Added-The subject or the legal representative of the subject is informed of the nature of this study and agrees to participate in all the terms of this study, and signs the informed consent form approved by the ethics committee of the clinical center.
Exclusion criteria
  • AddedConcurrent malignant tumors under treatment (such as during radiotherapy, chemotherapy, surgery, etc.).
  • Edited1. Currently undergoing treatment for malignant tumor (radiotherapy, chemotherapy, during surgery, etc.) 2. Current medical conditionsConcurrent diseases requiring urgent treatment (this criterionitem is not excluded after the condition ishas been stabilized after treatment):, such as acute infection, hypertensionhypertensive crisis, diabetic ketoacidosis, aortic dissection, etc.
  • RemovedCurrent severe heart failure (NYHA class 4) 4. Current liver failure (ALT or AST ≥ 5 times the upper limit of normal) or current renal failure (decreased renal function caused by any reason (defined as eGFR < 30mL/(min·1.73m2)) 5. Pregnant or lactating women, or women who plan to become pregnant during the study period 6. Current severe mental illness (except mild to moderate anxiety and depression) 7. Organ transplantation 8. Estimated survival time <3 years 9. Blood-borne infectious diseases: including HIV infection, AIDS, active hepatitis B, hepatitis C, etc.
  • RemovedAny condition considered inappropriate for participation in the study by the investigators.
  • AddedCurrently suffering from severe heart failure (NYHA grade 4).
  • AddedCurrently suffering from liver failure (ALT or AST ≥ 5 times the upper limit of normal) or current renal failure (any cause of renal function decline defined as eGFR < 15 mL/(min·1.73m2) or currently undergoing dialysis treatment).
  • AddedWomen who are pregnant or breastfeeding, or those planning to become pregnant during the research period.
  • AddedThose with severe mental illnesses (except for mild to moderate anxiety and depression).
  • AddedOrgan transplantation.
  • AddedExpected survival period < 3 years.
  • AddedBlood-borne infectious diseases, including HIV infection, AIDS, active hepatitis B, hepatitis C, etc.
  • AddedAny situation in which the researchers consider it unsuitable to participate in the study.
Nov 16, 2026
Interventions
Arm changed ASCVD cohort→Patients with panvascular disease cohort. Arms added: Patients with single disease cohort·High risk cohort; arms removed: healthy cohort
Nov 16, 2026
Title
Prospective Cohort Study of Panvascular Disease in China(PAN-China)
Nov 16, 2026
Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University→Second Affiliated Hospital, Zhejiang University, School of Medicine
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Active, not recruiting→Recruiting
    1 site added. 2 sites changed recruiting status (2 now active, not recruiting)
    Show 2 sites
    • Department of Cardiology, The Second Affiliated Hospital, School of Medicine, Zhejiang University · Hangzhou, Chinano status→Active, not recruiting
    • Second Affiliated Hospital, School of Medicine, Zhejiang University · Hangzhou, Chinano status→Active, not recruiting
    Show site
    • The Second Affiliated Hospital of Zhejiang University School of Medicine · Hangzhou, China
    Eligibility 5 inclusion criteria edited, 13 added, 2 removed; 1 exclusion criterion edited, 9 added, 2 removed
    What changed in the criteria
    Inclusion criteria
    • Removed1. Age ≥18 years old 2. Patients with panvascular disease: i.e., 2 or more of the following vascular diseases.
    • AddedAge ≥ 18 years old.
    • AddedMeet the inclusion criteria of any one of the following groups:
    • AddedGroup A: Patients with pan-vascular diseases. This refers to those involving two or more of the following vascular diseases:
    • Edited2.1 Coronary arteryarteries: 2.1.1 Coronary atherosclerotic heart disease:, including acute coronary syndrome, stable angina pectoris, moderate or more stenosis of theto severe coronary artery stenosis, history of myocardial infarction, and history of coronary revascularization such as stent implantation or bypass grafting.
    • Edited2.2. CerebrovascularCerebrovascular diseases: 2.2.1 Intracranial atherosclerotic disease:diseases, including ischemic stroke, transient ischemic attack, or moderate or more stenosis of the intracranial artery disease.
    • Edited2.2.2 CervicalCerebrovascular diseases: Carotid atherosclerotic disease:diseases, including carotid artery disease, and vertebral artery disease.
    • Edited2.3. Aorta: 2.3.1 Aortic atherosclerotic disease:Atherosclerotic aortic diseases, including severe aortic plaqueplaques, aortic ulcerulcers, aortic stenosis or atresia, aortic dissection, aortic aneurysm, etc.
    • Edited2.4. Peripheral arteries: 2.4.1 Upper limb atherosclerotic disease:Atherosclerotic diseases of the upper extremities, including diseases of the subclavian artery, axillary artery, brachial artery, and other sitesparts.
    • RemovedEdition 2 January 25, 2024 2.4.2 Renal atherosclerotic disease 2.4.3 Mesenteric atherosclerotic disease 2.4.4 Lower limb atherosclerotic disease 3. Clinical data and biological samples are available 4. The subjects or their legal representatives were informed of the nature of the study and agreed to all terms of participation in the study, and signed the informed consent approved by the ethics committee of each clinical center.
    • AddedPeripheral arteries: Mesenteric atherosclerotic disease.
    • AddedPeripheral arteries: Atherosclerotic disease of the renal artery.
    • AddedPeripheral arteries: Atherosclerotic disease of the lower extremity arteries.
    • AddedGroup B: Patients with a single atherosclerotic vascular disease of the above-mentioned arteries.
    • AddedGroup C: People at risk of pan-vascular disease. Must have at least one of the following:
    • AddedAbdominal obesity: Waist circumference ≥ 90 cm for men and ≥ 85 cm for women.
    • AddedFasting blood glucose ≥ 6.1 mmol/L and/or 2-hour postprandial blood glucose ≥ 7.8 mmol/L, and/or diabetes has been diagnosed and treated.
    • AddedBlood pressure ≥ 130/85 mmHg and/or have been diagnosed with hypertension and are receiving treatment.
    • AddedFasting high-density lipoprotein cholesterol < 1.04 mmol/L, and/or have been diagnosed with hyperlipidemia and are receiving treatment.
    • Added-The subject or the legal representative of the subject is informed of the nature of this study and agrees to participate in all the terms of this study, and signs the informed consent form approved by the ethics committee of the clinical center.
    Exclusion criteria
    • AddedConcurrent malignant tumors under treatment (such as during radiotherapy, chemotherapy, surgery, etc.).
    • Edited1. Currently undergoing treatment for malignant tumor (radiotherapy, chemotherapy, during surgery, etc.) 2. Current medical conditionsConcurrent diseases requiring urgent treatment (this criterionitem is not excluded after the condition ishas been stabilized after treatment):, such as acute infection, hypertensionhypertensive crisis, diabetic ketoacidosis, aortic dissection, etc.
    • RemovedCurrent severe heart failure (NYHA class 4) 4. Current liver failure (ALT or AST ≥ 5 times the upper limit of normal) or current renal failure (decreased renal function caused by any reason (defined as eGFR < 30mL/(min·1.73m2)) 5. Pregnant or lactating women, or women who plan to become pregnant during the study period 6. Current severe mental illness (except mild to moderate anxiety and depression) 7. Organ transplantation 8. Estimated survival time <3 years 9. Blood-borne infectious diseases: including HIV infection, AIDS, active hepatitis B, hepatitis C, etc.
    • RemovedAny condition considered inappropriate for participation in the study by the investigators.
    • AddedCurrently suffering from severe heart failure (NYHA grade 4).
    • AddedCurrently suffering from liver failure (ALT or AST ≥ 5 times the upper limit of normal) or current renal failure (any cause of renal function decline defined as eGFR < 15 mL/(min·1.73m2) or currently undergoing dialysis treatment).
    • AddedWomen who are pregnant or breastfeeding, or those planning to become pregnant during the research period.
    • AddedThose with severe mental illnesses (except for mild to moderate anxiety and depression).
    • AddedOrgan transplantation.
    • AddedExpected survival period < 3 years.
    • AddedBlood-borne infectious diseases, including HIV infection, AIDS, active hepatitis B, hepatitis C, etc.
    • AddedAny situation in which the researchers consider it unsuitable to participate in the study.
    Interventions Arm changed ASCVD cohort→Patients with panvascular disease cohort. Arms added: Patients with single disease cohort·High risk cohort; arms removed: healthy cohort
    Sponsor Second Affiliated Hospital, School of Medicine, Zhejiang University→Second Affiliated Hospital, Zhejiang University, School of Medicine
    Title Prospective Cohort Study of Panvascular Disease in China(PAN-China)
    + 2 other changes: verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06295861
Collaborators
The First Affiliated Hospital of Zhejiang Chinese Medical University, Huzhou Central Hospital, Affiliated Hospital of Jiaxing University, The Second Affiliated Hospital of Jiaxing University, Zhejiang Hospital, Ningbo No. 1 Hospital, Jinhua Central Hospital, Shaoxing People's Hospital, Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University, First Affiliated Hospital of Wenzhou Medical University, Lanxi People's Hospital, People's Hospital of Quzhou, Ningbo Medical Center Lihuili Hospital, Lishui Country People's Hospital, Affiliated Zhoushan Hospital of Wenzhou Medical University, Songyang County People's Hospital
Responsible party
Sponsor
First posted
Mar 6, 2024
Start date
Feb 21, 2024
Primary completion
Nov 30, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Nov 16, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion